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empirical antibiotic therapy for patients with suspected men-
ingitis caused by this microorganism has remained unknown.




 reported a 25 percent preva-




 isolates and a 9 per-
cent prevalence of cephalosporin-resistant isolates among 431
patients with invasive pneumococcal infections in Atlanta.
The authors recommended adding vancomycin to the initial
therapeutic regimen of patients with suspected pneumococcal
meningitis. Their suggestion appears questionable because
they did not present the susceptibility patterns of the menin-
geal strains or discuss morbidity and mortality, there are in-
sufficient published data to support their recommendation,
and the adjunctive use of dexamethasone may reduce the
penetration of vancomycin into the cerebrospinal fluid. In ad-
dition, there have been reports in the literature on the failure









nally, it has recently been shown that the clinical outcome of





resistant to broad-spectrum cephalosporins (minimal inhibi-









is similar to that of patients infected with susceptible strains
and that treatment with high doses of cefotaxime could be ap-




Before recommending the routine addition of vancomycin




meningitis, one should first demonstrate that its use is associ-
ated with a significant survival benefit. Another approach
would be to reserve the use of vancomycin for infections that




-lactam antibiotics, which would help de-
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the mortality rate in patients with pneumonia caused by pen-





treated with penicillin, cefotaxime, or ceftriaxone was similar
to that in patients infected with pneumococcal strains that
were sensitive to these drugs. In the accompanying study by
Hofmann et al., the prevalence of penicillin-resistant strains
was 25 percent and of cefotaxime-resistant strains 9 percent




 Neither report spe-
cifically mentioned ceftazidime. The data show that ceftazi-





The mortality rate for severe community-acquired pneumo-
nia is high (20 to 50 percent), and the most common etiologic
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). The 1993 recommendations of the American Thoracic
Society for empirical treatment include the use of a macrolide





 But the use of an agent such as ceftazidime, which is
approximately 16 times less active than cefotaxime against
penicillin-resistant strains, may not in fact yield results such




 The addition of eryth-
romycin to a regimen including ceftazidime may be of only
limited benefit in patients with penicillin- or cephalosporin-
resistant pneumococcal disease, given the rate of resistance to





Do Pallares et al. have any data on patients with penicil-
lin- or cephalosporin-resistant pneumococcal strains who were
treated with ceftazidime alone or on patients with erythro-
mycin-resistant strains who were treated with erythromycin
alone? If Hofmann et al. tested the pneumococcal strains
against ceftazidime, what was the overall resistance rate? What









g per milliliter)? It is in patients infected
with such strains that ceftazidime may fail as a therapeutic
agent.
Most patients with pneumonia are treated without a defi-
nite etiologic agent ever being identified. Many of these pa-
tients will have pneumococcal disease, and the efficacy of
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 We agree with Dr. Redondo that the optimal





been defined, especially for strains with intermediate levels of
drug resistance. Our comments were focused on the treat-













g per milliliter) to extended-spectrum cephalo-
sporins (i.e., cefotaxime and ceftriaxone). There are adequate
data to suggest that this condition should not be treated with









are frequently far less than that needed to achieve bactericid-
al activity against resistant strains. A synergistic effect occurs
when vancomycin is added to an extended-spectrum cepha-





 and recent data suggest that dexamethasone
therapy does not diminish levels of the drug achievable in cer-




In our study, 1 of 18 cerebrospinal isolates (6 percent) was




g per milliliter). Although
this number of isolates is too small to estimate the prevalence
of resistance, our data on 431 pneumococcal isolates from
normally sterile sites provide precise estimates of drug resist-
ance among pneumococci circulating in Atlanta during the
study period. Bacterial meningitis is a life-threatening infec-
tion with high mortality and the potential for severe neurolog-
ic sequelae if optimal therapy is delayed. In communities such









g per milliliter), it would be unreasonable
to await more clinical data before recommending that vanco-
mycin be added empirically to regimens including extended-
spectrum cephalosporins for the treatment of pneumococcal
meningitis. Vancomycin should be discontinued immediately
if the strain is susceptible to extended-spectrum cephalospor-
ins. For nonmeningeal infections, appropriate recommenda-
tions are not as clear. Additional outcome data and interim
consensus recommendations for treatment are critically need-
ed. We agree that routine use of vancomycin is not warranted
for the vast majority of pneumococcal infections and may pro-





recommendations were focused on meningitis in Atlanta,
where the prevalence of strains resistant to extended-spec-
trum cephalosporins is high; however, even if our recommen-
dations were applied nationally, limited use of vancomycin for
meningitis as we described would exert minimal selective
pressure, given that only 3000 cases of pneumococcal menin-
gitis occur in the United States annually and most patients
(with strains susceptible to extended-spectrum cephalospor-
ins) would be treated for only one to two days.








 Few communities in the
United States currently have access to timely surveillance





 will soon be conducted nationwide and
will provide clinicians with timely, community-specific infor-
mation for making rational choices for the empirical treat-




We did not test pneumococcal isolates for resistance to cef-
tazidime because it has poor activity against penicillin-resist-
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 We agree with Clynes that ceftazidime is much
less active against penicillin-resistant pneumococci than is cef-




 have previously re-





tibiotics with the poorest activity against pneumococci with
intermediate and high levels of resistance to penicillin. For
penicillin-resistant pneumococci, the MICs of ceftazidime




g per milliliter, whereas the MICs of cef-








Among the 35 pneumococcal strains isolated from our patients
with pneumonia that showed resistance to cefotaxime or cef-
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g per milliliter), the MICs of cefta-





We have no experience with patients with penicillin-resist-
ant pneumococcal pneumonia treated with ceftazidime alone.
The three patients infected with penicillin-resistant pneumo-
cocci who were treated with ceftazidime also received either
erythromycin or vancomycin, and the strains isolated were
susceptible to these drugs. However, pneumococcal pneumo-
nia developed in four patients during or shortly after a course
of ceftazidime therapy, and in these four cases the MICs of




g per milliliter. Therefore,
we believe that ceftazidime should not be used for the treat-
ment of penicillin-resistant pneumococcal pneumonia. We also
agree with Clynes that the addition of erythromycin to cefta-
zidime therapy may be of only limited benefit because of the
high frequency of erythromycin-resistant pneumococci that is
being reported worldwide.
Among our 34 patients with pneumococcal pneumonia who
were treated with erythromycin alone, there were no cases













therapy with erythromycin failed in two of six patients with
pneumococcal pneumonia because the strains were resistant
to erythromycin.
We believe that patients with pneumonia caused by pneu-








g per milliliter) should not be treated with this drug
and that clinicians should be cautious in prescribing erythro-
mycin for the empirical treatment of pneumonia, particularly
in areas with a high prevalence of resistant pneumococci.
On the basis of the current levels of resistance, we think
that most patients with severe pneumonia can be treated em-
pirically with ceftriaxone or cefotaxime plus erythromycin.
However, in selected patients with serious underlying condi-
tions (e.g., neutropenia), a regimen including erythromycin





























Barcelona, Spain Hospital de Bellvitge
 
1. Liñares J, Alonso T, Perez JL, et al. Decreased susceptibility of penicillin-




-lactam antibiotics. J Antimicrob
Chemother 1992;30:279-88.
2. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-
susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, cef-
triaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and
vancomycin. Antimicrob Agents Chemother 1994;38:898-900.
3. Moreno S, Garcia-Leoni ME, Cercenado E, Diaz MD, Bernaldo de Quiros





 incidence, risk factors, and response to therapy in a prospective
study. Clin Infect Dis 1995;20:1195-200.
 





 We are troubled by the strong conclusion of




 that “oral ganciclovir is safe and
effective as maintenance therapy for cytomegalovirus retini-
tis.” This statement implies equivalence between intravenous
and oral ganciclovir, which we believe is not convincingly sup-
ported by the data.
When there is no difference between the treatment groups,
one does not accept the null hypothesis but rather fails to
reject it. In other words, if the data show there is no differ-
ence between intravenous and oral ganciclovir, it does not
imply they are equivalent but rather that there is not suffi-
cient evidence to conclude that oral is worse than intrave-
nous ganciclovir.
The sample size was too small to detect the stated differ-
ence of 25 days in the time to progression between treatment
groups with 80 percent power. With the use of a mean time
to progression of 70 days for the intravenous-ganciclovir
group and 45 days for the oral-ganciclovir group, 120 patients
(60 per group), a two-sided type I error of 0.05, an accrual
period of 15 months, and a 20-week follow-up period, the




 With the inclusion of only 115 patients
capable of being evaluated, the power drops to 65 percent. To
achieve a power of 80 percent, 162 patients needed to be eval-
uated.
Given the above calculations along with the conflicting re-
sults of the funduscopic and photographic evaluations with
respect to the time to progression and the occurrence of new
cytomegalovirus retinitis in the previously uninvolved eye, we
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 Why did Drew et al. calculate the intravenous
dose on the basis of body weight (i.e., milligrams per kilo-
gram of body weight) and give the oral maintenance therapy
in an arbitrary dose of 3000 mg per day in six divided doses?
The authors do not provide information on the specific anti-
retroviral agents used in each group, and marrow suppression
and sepsis may be related to the additive toxic effects induced
by the combination of zidovudine and ganciclovir.
Failures after successful induction therapy may reflect not
the natural history of the disease, but the failure of physicians
to prescribe an adequate maintenance dose of ganciclovir to
suppress the virus effectively. For several years I have pre-
scribed maintenance doses of 8 to 10 mg per kilogram daily
and generally do not see a recurrence of cytomegalovirus ret-
initis in less than 9 to 12 months when this dose is tolerated.
As a rule, this dose is tolerated. I generally avoid using con-
comitant zidovudine therapy and have not seen frequent sep-
tic episodes. I monitor platelet counts because they rise with
ganciclovir therapy, reflecting the suppression of these mar-
row elements by systemic cytomegalovirus.
That the patients were instructed to take 500 mg of ganci-
clovir six times per day rather than 1000 mg three times per
day, as is now generally prescribed and is clearly more con-
venient, suggests that the authors are aware of the decreased
bioavailability of the drug as the bulk of drug exposed to the
gut is increased. Missed doses, in practice, may promote viral
resistance, and this may become a bigger problem as use of
















 Dr. Torgovnick raises several interesting ques-
tions. There is no rationale for varying the oral dose accord-
ing to weight, since pharmacokinetic studies of oral ganciclo-
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